Plain-English translation of NCT05835505 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This clinical trial is testing whether hydroxocobalamin (a form of vitamin B12) can help treat primary sclerosing cholangitis, a disease where bile ducts in the liver become scarred and damaged. You would take this medication (or a placebo) by mouth twice a day for 4 weeks, and some participants may also receive an IV dose. The study lasts 8 weeks total and involves 9 visits, which can all happen remotely with a nurse visiting your home for blood and stool samples.
Primary sclerosing cholangitis is a serious liver disease that gradually damages the bile ducts and currently has limited treatment options. Researchers believe this medication might help reduce harmful substances in the liver and slow or improve the disease.
You likely qualify if…
You likely don't qualify if…
Over 8 weeks, you would take the medication (or placebo) by mouth twice daily for 4 weeks, then switch to the other treatment for 4 weeks. Some participants in certain groups will also receive a single IV infusion. You'll attend 9 study visits (all remote), keep a medication log, and have blood drawn and stool samples collected a few times—a research nurse will come to your home for these samples to make it convenient for you.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
United States